Corcept Therapeutics Incorporated provided earnings guidance for the full year of 2022. For the period, the company expects revenue to be in the range of $400 million and $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.88 USD | +5.03% | +4.00% | +1.22% |
11:38am | Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating | MT |
28/05 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.22% | 3.26B | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Earnings Guidance for the Full Year of 2022